Literature DB >> 14676279

Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.

David Goldschneider1, Etienne Blanc, Gilda Raguénez, Michel Barrois, Agnès Legrand, Gwenaëlle Le Roux, Hedi Haddada, Jean Bénard, Sétha Douc-Rasy.   

Abstract

p73, the first p53 gene homologue, encodes an array of p73 proteins including p73 alpha full-length (TAp73 alpha) and amino-truncated isoforms (Delta Np73 alpha), two proteins with opposite biological functions. TAp73 alpha can induce tumor suppressive properties, while Delta Np73 alpha antagonizes p53 as well as TAp73 in a dominant-negative manner. In human malignant neuroblasts, p53 protein is wild-type but known to be excluded from the nucleus, therefore disabling its function as a tumor suppressor. The present study investigates whether there is a functional link between p73 isoforms and p53 in neuroblastoma. Experiments were performed on two neuroblastoma cell lines differing in their p53 status, e.g. wild-type p53 SH-5Y5Y cells and mutated p53 IGR-N-91 cells. Data indicate that (i) both TA- and Delta N-p73 alpha enhance p53 protein level in SH-SY5Y cells, whereas level remains unchanged in IGR-N-91 cells; (ii) only in SH-SY5Y cells does forced TAp73 alpha overexpression markedly induce nuclear accumulation of p53 protein; (iii) p21 protein expression is increased in both cell lines infected with TAp73, suggesting that, in IGR-N-91 cells, p21 is induced by p73 through a p53-independent pathway; (iv) in the SHSY5Y cell line, Btg2 expression is strongly enhanced in cells overexpressing TA, and to a lesser extent in cells overexpressing Delta N. Taken together our results suggest that TAp73 may restore p53 function in NB with wild-type nonfunctional p53, but not in NB with mutated p53.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14676279     DOI: 10.1242/jcs.00834

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  15 in total

1.  DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.

Authors:  A P Simões-Wüst; B Sigrist; L Belyanskaya; S Hopkins Donaldson; R A Stahel; U Zangemeister-Wittke
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

Review 2.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

3.  PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers.

Authors:  P Klanrit; P Taebunpakul; M B Flinterman; E W Odell; M A Riaz; G Melino; P Salomoni; J S Mymryk; J Gäken; F Farzaneh; M Tavassoli
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

4.  Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.

Authors:  Subhasree Roy Choudhury; Surajit Karmakar; Naren L Banik; Swapan K Ray
Journal:  Invest New Drugs       Date:  2009-09-24       Impact factor: 3.850

5.  Role of activating transcription factor 3 on TAp73 stability and apoptosis in paclitaxel-treated cervical cancer cells.

Authors:  Yeo Kyoung Oh; Hyun Jung Lee; Mi-Hee Jeong; Marie Rhee; Ji-Won Mo; Eun Hyeon Song; Joong-Yeon Lim; Kyung-Hee Choi; Inho Jo; Sang Ick Park; Bin Gao; Yongil Kwon; Won-Ho Kim
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

6.  Expression of C-terminal deleted p53 isoforms in neuroblastoma.

Authors:  David Goldschneider; Emilie Horvilleur; Louis-François Plassa; Marine Guillaud-Bataille; Karine Million; Evelyne Wittmer-Dupret; Gisèle Danglot; Hughes de Thé; Jean Bénard; Evelyne May; Sétha Douc-Rasy
Journal:  Nucleic Acids Res       Date:  2006-10-05       Impact factor: 16.971

7.  p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.

Authors:  Emilie Horvilleur; Matthieu Bauer; David Goldschneider; Xénia Mergui; Alix de la Motte; Jean Bénard; Sétha Douc-Rasy; David Cappellen
Journal:  Nucleic Acids Res       Date:  2008-06-25       Impact factor: 16.971

8.  Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.

Authors:  Valérie Combaret; Sandrine Boyault; Isabelle Iacono; Stéphanie Brejon; Raphaël Rousseau; Alain Puisieux
Journal:  Mol Cancer       Date:  2008-06-05       Impact factor: 27.401

Review 9.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

10.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.